Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 2Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 102Neoplasm Metastasis 26Neoplasms 15Brain Neoplasms 13Prostatic Neoplasms 10Endometrial Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 7Glioblastoma 7Glioma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Breast Diseases 5Sarcoma 4Recurrence 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Sarcoma, Ewing 3Osteosarcoma 3Neoplasms by Site 3Multiple Myeloma 3Meningioma 3Melanoma 3Carcinoma, Renal Cell 3Unilateral Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Oligodendroglioma 2

Interventions

Fluorouracil 497Bevacizumab 476Oxaliplatin 449Leucovorin 440Irinotecan 408Cetuximab 317Capecitabine 317pembrolizumab 142Folfox protocol 129Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 81IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 46Neoadjuvant Therapy 45Standard of Care 44Magnetic Resonance Spectroscopy 43Biopsy 43Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 38Surveys and Questionnaires 38Cyclophosphamide 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Colorectal Neoplasms × abemaciclib × Clear all
NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
210 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04165031 2021-11-24

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Eli Lilly and Company

Phase 1/2 Terminated
5 enrolled 9 charts
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡